11–37 Ch. 11—Problems
Problem 11-9, Continued
Consolidating the Foreign Subsidiary
Balfour Corporation and Tobac, Inc.
Worksheet for Consolidated Financial Statements (in dollars)
For Year Ended December 31, 2017
Eliminations Consolidated Consolidated
Trial Balance
and Adjustments Income Balance
Balfour
Tobac Dr Cr Statement Sheet
Cash ……………………………………………………………. 4,463,200 2,006,800 …………….. ………..…… ………………… 6,470,000
Net Accounts Receivable ……………………………….. 15,350,000 7,800,000 …………….. …………….. ………………… 23,150,000
Depreciable Assets ……………………………………….. 68,000,000 19,060,000 …………….. ………….…. ………………… 87,060,000
Equipment ……………………………………………………. ……………… ………………. (D/A) 1,650,000 …………….. ………………… 1,650,000
Accumulated Depreciation ……………………………… (42,000,000) (6,792,000) …………….. (D/A) 412,500 ..………………. (49,204,500)
Due to Balfour ………………………………………………. ……………… (1,356,800) (LN1) 1,356,800 …………….. ………………… ……………….
Exchange Gain on Balfour Loan ……………………… ……………… (20,615) …………….. …………….. (20,615) ……………….
Other Expenses ……………………………………………. 10,000,000 3,358,452 (D/A) 165,000 …………….. 13,523,452 ……………….
Interest Income …………………………………………….. (76,800) ………………. (LN2) 76,800 …………….. ………………… ……………….
Subsidiary Income …………………………………………. (3,495,363) ………………. (CY1) 3,495,363 …………….. ………………… ……………….